Annals of Surgical Oncology

, Volume 15, Issue 7, pp 2042–2052 | Cite as

Perioperative Use of β-blockers and COX-2 Inhibitors May Improve Immune Competence and Reduce the Risk of Tumor Metastasis

  • Marganit Benish
  • Inbal Bartal
  • Yael Goldfarb
  • Ben Levi
  • Roi Avraham
  • Amiram Raz
  • Shamgar Ben-Eliyahu
Gastrointestinal Oncology

Abstract

Background

COX inhibitors and β-blockers were recently suggested to reduce cancer progression through inhibition of tumor proliferation and growth factor secretion, induction of tumor apoptosis, and prevention of cellular immune suppression during the critical perioperative period. Here we evaluated the perioperative impact of clinically applicable drugs from these categories in the context of surgery, studying natural killer (NK) cell activity and resistance to experimental metastases.

Methods

F344 rats were treated with COX-1 inhibitors (SC560), COX-2 inhibitors (indomethacin, etodolac, or celecoxib), a β-blocker (propranolol), or a combination of a COX-2 inhibitor and a β-blocker (etodolac and propranolol). Rats underwent laparotomy, and were inoculated intravenously with syngeneic MADB106 tumor cells for the assessment of lung tumor retention (LTR). Additionally, the impact of these drug regimens on postoperative levels of NK cytotoxicity was studied in peripheral blood and marginating-pulmonary leukocytes.

Results

Surgery increased MADB106 LTR. COX-2 inhibition, but not COX-1 inhibition, reduced postoperative LTR. Etodolac and propranolol both attenuated the deleterious impact of surgery, and their combined use abolished it. Surgery decreased NK cytotoxicity per NK cell in both immune compartments, and only the combination of etodolac and propranolol significantly attenuated these effects. Lastly, the initiation of drug treatment three days prior to surgery yielded the same beneficial effects as a single pre-operative administration, but, as discussed, prolonged treatment may be more advantageous clinically.

Conclusions

Excess prostaglandin and catecholamine release contributes to postoperative immune-suppression. Treatment combining perioperative COX-2 inhibition and β-blockade is practical in operated cancer patients, and our study suggests potential immunological and clinical benefits.

Keywords

COX-2 inhibitors β-Adrenergic blockers Metastases Perioperative 

Notes

Acknowledgement

Support was provided by NIH/NCI CA125456 grant (S. B-E) and by a grant from the Israel-USA Binational Science Foundation (S. B-E).

References

  1. 1.
    Menetrier-Caux C, Bain C, Favrot MC, et al. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br J Cancer 1999; 79:119–30PubMedCrossRefGoogle Scholar
  2. 2.
    Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 1997; 20:165–77PubMedCrossRefGoogle Scholar
  3. 3.
    Roche-Nagle G, Connolly EM, Eng M, et al. Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br J Cancer 2004; 91:359–65PubMedGoogle Scholar
  4. 4.
    Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004; 23:63–75PubMedCrossRefGoogle Scholar
  5. 5.
    Kern MA, Haugg AM, Koch AF, et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 2006; 66:7059–66PubMedCrossRefGoogle Scholar
  6. 6.
    Wei D, Wang L, He Y, et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004; 64:2030–8PubMedCrossRefGoogle Scholar
  7. 7.
    Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5:1418–23PubMedCrossRefGoogle Scholar
  8. 8.
    Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001; 93:497–506PubMedCrossRefGoogle Scholar
  9. 9.
    Yang EV, Sood AK, Chen M, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006; 66:10357–64PubMedCrossRefGoogle Scholar
  10. 10.
    Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006; 12:939–44PubMedCrossRefGoogle Scholar
  11. 11.
    Masur K, Niggemann B, Zanker KS, et al. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001; 61:2866–9PubMedGoogle Scholar
  12. 12.
    Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003; 9:4514–21PubMedGoogle Scholar
  13. 13.
    Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006; 12:369–75PubMedCrossRefGoogle Scholar
  14. 14.
    Greenfeld K, Avraham R, Benish M, et al. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun 2007; 21:503–13PubMedCrossRefGoogle Scholar
  15. 15.
    Melamed R, Rosenne E, Shakhar K, et al. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun 2005; 19:114–26PubMedCrossRefGoogle Scholar
  16. 16.
    Shi JM, Lai SG, Xu CJ, et al. Pharmacokinetic difference between S-(+)- and R-(−)-etodolac in rats. Acta Pharmacol Sin 2004; 25:996–9PubMedGoogle Scholar
  17. 17.
    Hetu PO, Riendeau D. Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. Biochem J 2005; 391:561–6PubMedCrossRefGoogle Scholar
  18. 18.
    Adami M, Coppelli G, Guaita E, et al. Effects of cyclooxygenase-1 and -2 inhibition on gastric acid secretion and cardiovascular functions in rats. Pharmacology 2006; 76:84–92PubMedCrossRefGoogle Scholar
  19. 19.
    Page GG, Ben-Eliyahu S, Liebeskind JC. The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 1994; 8:241–50PubMedCrossRefGoogle Scholar
  20. 20.
    Bar-Yosef S, Melamed R, Page GG, et al. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology 2001; 94:1066–73PubMedCrossRefGoogle Scholar
  21. 21.
    Ben-Eliyahu S, Page GG. In vivo assessment of natural killer cell activity in rats. Prog Neuroendocrineimmunol 1992; 5:199–214Google Scholar
  22. 22.
    Ben-Eliyahu S, Page GG, Yirmiya R, et al. Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat Med 1996; 2:457–60PubMedCrossRefGoogle Scholar
  23. 23.
    Shakhar G, Ben-Eliyahu S. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol 1998; 160:3251–8PubMedGoogle Scholar
  24. 24.
    Barlozzari T, Reynolds CW, Herberman RB. In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J Immunol 1983; 131:1024–7PubMedGoogle Scholar
  25. 25.
    Barlozzari T, Leonhardt J, Wiltrout RH, et al. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 1985; 134:2783–9PubMedGoogle Scholar
  26. 26.
    Shakhar G, Abudarham N, Melamed R, et al. Amelioration of operation-induced suppression of marginating pulmonary NK activity using poly IC: a potential approach to reduce postoperative metastasis. Ann Surg Oncol 2007; 14:841–52PubMedCrossRefGoogle Scholar
  27. 27.
    Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. J Leukoc Biol 2006; 79:1093–104PubMedCrossRefGoogle Scholar
  28. 28.
    Whalen MM, Bankhurst AD. Effects of beta-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function. Biochem J 1990; 272:327–31PubMedGoogle Scholar
  29. 29.
    Walker W, Rotondo D. Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis. Immunology 2004; 111:298–305PubMedCrossRefGoogle Scholar
  30. 30.
    Malygin AM, Meri S, Timonen T. Regulation of natural killer cell activity by transforming growth factor-beta and prostaglandin E2. Scand J Immunol 1993; 37:71–6PubMedCrossRefGoogle Scholar
  31. 31.
    Chouaib S, Welte K, Mertelsmann R, et al. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol 1985; 135:1172–9PubMedGoogle Scholar
  32. 32.
    Tamir A, Isakov N. Cyclic AMP inhibits phosphatidylinositol-coupled and -uncoupled mitogenic signals in T lymphocytes. Evidence that cAMP alters PKC-induced transcription regulation of members of the jun and fos family of genes. J Immunol 1994; 152:3391–9PubMedGoogle Scholar
  33. 33.
    Torgersen KM, Vaage JT, Levy FO, et al. Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity. J Biol Chem 1997; 272:5495–500PubMedCrossRefGoogle Scholar
  34. 34.
    Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164:361–70PubMedGoogle Scholar
  35. 35.
    van der Pouw Kraan TC, Boeije LC, Smeenk RJ, et al. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995; 181:775–9PubMedCrossRefGoogle Scholar
  36. 36.
    Elenkov IJ, Chrousos GP, Wilder RL. Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical implications. Ann NY Acad Sci 2000; 917:94–105PubMedGoogle Scholar
  37. 37.
    Elenkov IJ, Papanicolaou DA, Wilder RL, et al. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians 1996; 108:374–81PubMedGoogle Scholar
  38. 38.
    Menger MD, Vollmar B. Surgical trauma: hyperinflammation versus immunosuppression? Langenbecks Arch Surg 2004; 389:475–84PubMedCrossRefGoogle Scholar
  39. 39.
    Rosenne E, Shakhar G, Melamed R, et al. Inducing a mode of NK-resistance to suppression by stress and surgery: a potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis. Brain Behav Immun 2007; 21:395–408PubMedCrossRefGoogle Scholar
  40. 40.
    Cao Y, Pearman AT, Zimmerman GA, et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000; 97:11280–5PubMedCrossRefGoogle Scholar
  41. 41.
    Zha S, Yegnasubramanian V, Nelson WG, et al. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004; 215:1–20PubMedCrossRefGoogle Scholar
  42. 42.
    Kundu N, Walser TC, Ma X, et al. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 2005; 54:981–7PubMedCrossRefGoogle Scholar
  43. 43.
    Sacerdote P, Manfredi B, Bianchi M, et al. Intermittent but not continuous inescapable footshock stress affects immune responses and immunocyte beta-endorphin concentrations in the rat. Brain Behav Immun 1994; 8:251–60PubMedCrossRefGoogle Scholar
  44. 44.
    Lewis JW, Shavit Y, Terman GW, et al. Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth. Peptides 1983; 4:635–8PubMedCrossRefGoogle Scholar
  45. 45.
    Shavit Y, Martin FC. Opioids, stress, and immunity: animal studies. Ann Behav Med 1987; 9:11–15CrossRefGoogle Scholar
  46. 46.
    Shavit Y, Ben-Eliyahu S, Zeidel A, et al. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation 2004; 11:255–60PubMedCrossRefGoogle Scholar
  47. 47.
    Exadaktylos AK, Buggy DJ, Moriarty DC, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006; 105:660–4PubMedCrossRefGoogle Scholar
  48. 48.
    Beilin B, Shavit Y, Hart J, et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg 1996; 82:492–7PubMedCrossRefGoogle Scholar
  49. 49.
    Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62:4491–8PubMedGoogle Scholar
  50. 50.
    Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000; 91:1221–5PubMedCrossRefGoogle Scholar
  51. 51.
    Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002; 51:189–92PubMedCrossRefGoogle Scholar
  52. 52.
    Vaiva G, Ducrocq F, Jezequel K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003; 54:947–9PubMedCrossRefGoogle Scholar
  53. 53.
    Lutgendorf SK, Sood AK, Anderson B, et al. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol 2005; 23:7105–13PubMedCrossRefGoogle Scholar
  54. 54.
    Spiegel D, Sephton SE, Terr AI, et al. Effects of psychosocial treatment in prolonging cancer survival may be mediated by neuroimmune pathways. Ann NY Acad Sci 1998; 840:674–83PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Marganit Benish
    • 1
  • Inbal Bartal
    • 1
  • Yael Goldfarb
    • 1
  • Ben Levi
    • 1
  • Roi Avraham
    • 1
  • Amiram Raz
    • 2
  • Shamgar Ben-Eliyahu
    • 1
    • 3
  1. 1.NeuroImmunology Research Unit, Department of PsychologyTel Aviv UniversityTel AvivIsrael
  2. 2.Department of BiochemistryTel Aviv UniversityTel AvivIsrael
  3. 3.Outcomes Research(TM) InstituteLouisvilleUSA

Personalised recommendations